Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development

Eran Nizri; Michal Irony-Tur-Sinai; Nikolaos Grigoriadis; Oded Abramsky; Gabi Amitai; Talma Brenner

doi:10.1159/000097628

Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development

Eran Nizri, Michal Irony-Tur-Sinai, Nikolaos Grigoriadis, Oded Abramsky, Gabi Amitai, Talma Brenner^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Drug development, and especially that intended for central nervous system (CNS) disorders, still poses a challenge. We investigated both the use of bifunctional compounds designed for multiple targeting and enhanced CNS permeability, and of recombinant α-fetoprotein (AFP), a natural pregnancy-associated immunomodulating protein for the treatment of CNS inflammation. Bifunctional compounds showed a novel pharmacokinetic profile due to the conjugation, yet retained, and even improved pharmacodynamics. AFP was well tolerated and decreased various aspects of neuroinflammation, including disease severity, axonal loss and damage, T-cell reactivity, and antigen presentation. Our results show that both strategies may serve as future drug modalities.

Original language	English
Pages (from-to)	42-49
Number of pages	8
Journal	Pharmacology
Volume	79
Issue number	1
DOIs	https://doi.org/10.1159/000097628
State	Published - Jan 2007
Externally published	Yes

Keywords

Bifunctional molecules
Central nervous system inflammation
Drug development
Experimental autoimmune encephalomyelitis
Multiple sclerosis
Natural immunomodulating protein
α-Fetoprotein

Access to Document

10.1159/000097628

Cite this

@article{19e81dee34e549469438a290331af821,

title = "Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development",

abstract = "Drug development, and especially that intended for central nervous system (CNS) disorders, still poses a challenge. We investigated both the use of bifunctional compounds designed for multiple targeting and enhanced CNS permeability, and of recombinant α-fetoprotein (AFP), a natural pregnancy-associated immunomodulating protein for the treatment of CNS inflammation. Bifunctional compounds showed a novel pharmacokinetic profile due to the conjugation, yet retained, and even improved pharmacodynamics. AFP was well tolerated and decreased various aspects of neuroinflammation, including disease severity, axonal loss and damage, T-cell reactivity, and antigen presentation. Our results show that both strategies may serve as future drug modalities.",

keywords = "Bifunctional molecules, Central nervous system inflammation, Drug development, Experimental autoimmune encephalomyelitis, Multiple sclerosis, Natural immunomodulating protein, α-Fetoprotein",

author = "Eran Nizri and Michal Irony-Tur-Sinai and Nikolaos Grigoriadis and Oded Abramsky and Gabi Amitai and Talma Brenner",

year = "2007",

month = jan,

doi = "10.1159/000097628",

language = "אנגלית",

volume = "79",

pages = "42--49",

journal = "Pharmacology",

issn = "0031-7012",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development

AU - Nizri, Eran

AU - Irony-Tur-Sinai, Michal

AU - Grigoriadis, Nikolaos

AU - Abramsky, Oded

AU - Amitai, Gabi

AU - Brenner, Talma

PY - 2007/1

Y1 - 2007/1

N2 - Drug development, and especially that intended for central nervous system (CNS) disorders, still poses a challenge. We investigated both the use of bifunctional compounds designed for multiple targeting and enhanced CNS permeability, and of recombinant α-fetoprotein (AFP), a natural pregnancy-associated immunomodulating protein for the treatment of CNS inflammation. Bifunctional compounds showed a novel pharmacokinetic profile due to the conjugation, yet retained, and even improved pharmacodynamics. AFP was well tolerated and decreased various aspects of neuroinflammation, including disease severity, axonal loss and damage, T-cell reactivity, and antigen presentation. Our results show that both strategies may serve as future drug modalities.

AB - Drug development, and especially that intended for central nervous system (CNS) disorders, still poses a challenge. We investigated both the use of bifunctional compounds designed for multiple targeting and enhanced CNS permeability, and of recombinant α-fetoprotein (AFP), a natural pregnancy-associated immunomodulating protein for the treatment of CNS inflammation. Bifunctional compounds showed a novel pharmacokinetic profile due to the conjugation, yet retained, and even improved pharmacodynamics. AFP was well tolerated and decreased various aspects of neuroinflammation, including disease severity, axonal loss and damage, T-cell reactivity, and antigen presentation. Our results show that both strategies may serve as future drug modalities.

KW - Bifunctional molecules

KW - Central nervous system inflammation

KW - Drug development

KW - Experimental autoimmune encephalomyelitis

KW - Multiple sclerosis

KW - Natural immunomodulating protein

KW - α-Fetoprotein

UR - http://www.scopus.com/inward/record.url?scp=33845940740&partnerID=8YFLogxK

U2 - 10.1159/000097628

DO - 10.1159/000097628

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 17139193

AN - SCOPUS:33845940740

SN - 0031-7012

VL - 79

SP - 42

EP - 49

JO - Pharmacology

JF - Pharmacology

IS - 1

ER -

Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this